Form 4: Vir Biotechnology Director Robert More Acquires Significant Equity and Stock Options

Vir Biotechnology, Inc. Director Robert More has reported the acquisition of 8,000 restricted stock units and 16,000 stock options, signaling increased direct equity interest in the company.

Summary

• Robert J. More, a Director of Vir Biotechnology, Inc., acquired 8,000 shares of Common Stock in the form of Restricted Stock Units (RSUs) on May 30, 2025, pursuant to the Issuer's Equity Incentive Plan.
• These 8,000 RSUs will vest in full on May 30, 2026.
• Additionally, Mr. More acquired 16,000 stock options with an exercise price of $4.94 per share on May 30, 2025.
• The shares subject to these stock options will vest and become exercisable in full on May 30, 2026, and the options expire on May 29, 2035.
• Following these transactions, Mr. More directly beneficially owns 54,683 shares of Common Stock and 16,000 stock options.
• Mr. More also indirectly beneficially owns 495,890 shares of Common Stock held by Alta Partners NextGen Fund I, L.P., where he is a managing director of the general partner, though he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The acquisition of equity and options by a director is generally a positive signal, indicating continued commitment and alignment with the company's future performance. While it's compensation, it increases the insider's stake.

Positives

• The acquisition of 8,000 Restricted Stock Units (RSUs) and 16,000 stock options directly aligns the director's interests with long-term shareholder value.
• The grant of equity incentives at a $0 price for RSUs and a $0 price for options (as a grant, not exercise) is a common practice to incentivize directors and management.
• The vesting schedule for both RSUs and stock options on May 30, 2026, provides a clear timeline for the director's increased direct ownership.

Risks

• The reporting person disclaims beneficial ownership of the 495,890 shares held by Alta Partners NextGen Fund I, L.P., except to the extent of his pecuniary interest, which could imply limited direct control or influence over these specific shares despite his role.

Future Outlook

The document indicates future vesting of restricted stock units and stock options on May 30, 2026, which will increase the director's direct equity holdings in Vir Biotechnology.

Industry Context

This Form 4 filing reflects a routine insider transaction, specifically the grant of equity compensation to a director, which is a common practice across the biotechnology and broader corporate sectors to align management and director incentives with shareholder interests. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• Robert More indirectly beneficially owns 495,890 shares held by Alta Partners NextGen Fund I, L.P., as he is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. He disclaims beneficial ownership except for his pecuniary interest.

Stakeholder Impact

• Shareholders: The director's increased equity stake may be viewed as a positive signal of confidence in the company's future prospects.
• Employees: No direct impact mentioned, but general positive sentiment from director equity alignment could indirectly benefit morale.
• Management: The equity grants are part of compensation, aligning the director with management's goals.

Next Steps

• The 8,000 Restricted Stock Units (RSUs) are scheduled to vest in full on May 30, 2026.
• The 16,000 stock options are scheduled to vest and become exercisable in full on May 30, 2026.

Key Dates

Keywords

Vir Biotechnology, VIR, Form 4, insider transaction, restricted stock units, RSUs, stock options, equity incentive plan, director compensation, beneficial ownership, biotechnology